Methods of treating vitiligo using PD-1 binding antibodies

Patent metadata

Field	Value
Publication number	US-10766958-B2
Application number	US-201715707906-A
Country	US
Kind code	B2
Filing date	Sep 18, 2017
Priority date	Sep 19, 2016
Publication date	Sep 8, 2020
Grant date	Sep 8, 2020

Abstract

Provided herein are methods for managing, treating, or preventing vitiligo using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.

First claim

What is claimed:

1. A method of managing or treating vitiligo in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to PD-1, wherein the antibody or antigen-binding fragment comprises:
a light chain variable region (VL) comprising:
a VL complementarity determining region 1 (CDR1) comprising SEQ ID NO:1,
a VL CDR2 comprising SEQ ID NO:2, and
a VL CDR3 comprising SEQ ID NO:3; and

a heavy chain variable region (VH) comprising:
a VH CDR1 comprising SEQ ID NO:4,
a VH CDR2 comprising SEQ ID NO:5, and
a VH CDR3 comprising SEQ ID NO:6.

2. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence of SEQ ID NO:8.

3. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a VL comprising an amino acid sequence of SEQ ID NO:10.

4. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence of SEQ ID NO:11.

5. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence of SEQ ID NO:12.

6. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a VH comprising an amino acid sequence of SEQ ID NO:13.

7. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises
a VL comprising an amino acid sequence of SEQ ID NO:8; and
a VH comprising an amino acid sequence of SEQ ID NO:11.

8. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises
a VL comprising an amino acid sequence of SEQ ID NO:8; and
a VH comprising an amino acid sequence of SEQ ID NO:12.

9. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises
a VL comprising an amino acid sequence of SEQ ID NO:8; and
a VH comprising an amino acid sequence of SEQ ID NO:13.

10. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises
a VL comprising an amino acid sequence of SEQ ID NO:10; and
a VH comprising an amino acid sequence of SEQ ID NO:11.

11. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises
a VL comprising an amino acid sequence of SEQ ID NO:10; and
a VH comprising an amino acid sequence of SEQ ID NO:12.

12. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises
a VL comprising an amino acid sequence of SEQ ID NO:10; and
a VH comprising an amino acid sequence of SEQ ID NO:13.

13. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

14. The method of claim 9 , wherein the antibody or antigen-binding fragment comprises a human IgG1 Fc region, or a mutant thereof.

15. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

16. The method of claim 9 , wherein the antibody or antigen-binding fragment comprises a human IgG1-K322A Fc region.

17. The method of 1 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

18. The method of 9 , wherein the antibody or antigen-binding fragment comprises a human IgG4 Fc region, or a mutant thereof.

19. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

20. The method of claim 9 , wherein the antibody or antigen-binding fragment comprises a human IgG4P Fc region.

21. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

22. The method of claim 9 , wherein the antibody or antigen-binding fragment comprises a human IgG4PE Fc region.

23. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

24. The method of claim 7 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

25. The method of claim 8 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

26. The method of claim 9 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

27. The method of claim 10 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

28. The method of claim 11 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

29. The method of claim 12 , wherein the antibody or antigen-binding fragment comprises a heavy chain Fc region comprising an amino acid sequence selected from the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39 or SEQ ID NO:40.

30. The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

31. The method of claim 7 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

32. The method of claim 8 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

33. The method of claim 9 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

34. The method of claim 10 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

35. The method of claim 11 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

36. The method of claim 12 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

37. The method of claim 23 , wherein the antibody or antigen-binding fragment further comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

38. The method of claim 24 , wherein the antibody or antigen-binding fragment comprises a light chain constant region comprising an amino acid sequence of SEQ ID NO:41.

39. The method of claim 25 , wherein the antibody or antigen-binding fragm

Assignees

• Celgene Corp

Inventors

• Ringheim Garth E

Classifications

• C07K2317/71

  Decreased effector function due to an Fc-modification · CPC title

• C07K2317/734

  Complement-dependent cytotoxicity [CDC] · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title